FILE - This Feb. 19, 2013 file photo shows OxyContin pills arranged for a photo at a pharmacy in Montpelier, Vt. Connecticut-based Purdue Pharma, the maker of the powerful painkiller OxyContin has agreed to provide access to propriety research and other data to addiction researchers at Oklahoma State University to help them find causes and treatments for drug addiction. (AP Photo/Toby Talbot, File)
Purdue Pharma in settlement talks over 2,000 lawsuits
02:16 - Source: CNN
CNN  — 

The Sackler family could give up its ownership of Purdue Pharma and up to $4.5 billion of their own money, as one possible settlement option over the more than 2,000 lawsuits filed against their company, a person with knowledge of the negotiations tells CNN.

The source said the Sacklers would no longer own Purdue Pharma and pay $3 billion out of pocket, plus up to another $1.5 billion dependent on the sale of the company. In this framework, Purdue’s bankruptcy claim is being contemplated as a strategy to preserve the value of the company and pay out as many settlements as possible, the source added.

Purdue Pharma, which manufactures OxyContin, is at the center of the opioid crisis in America.

Yesterday, two state attorneys general involved in the talks indicated the negotiations with the Sackler family had broken down, according to a letter provided to CNN by a person with knowledge of the negotiations.

According to the letter, the Sacklers have rejected two proposals, which included a payment of $4.5 billion to creditors and the states. No counter offers were given. The attorneys general from Tennessee and North Carolina also write they expect Purdue Pharma to file for bankruptcy protection “imminently.”

A Purdue spokeswoman yesterday reaffirmed to CNN that the company wants to settle and “believes a settlement that benefits the American public now is a far better path than years of wasteful litigation and appeals.”

Previous reports from The New York Times, the Washington Post and NBC news said that the Sackler family would give up ownership of Purdue Pharma and pay at least $3 billion of its own money under terms of the settlement proposal.